keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic pancreatic cancer

keyword
https://www.readbyqxmd.com/read/29454229/pancreatic-cancer-presenting-as-colonic-disease-a-rare-case-report
#1
Sara Tavares Nogueira, Bruno Lima Pinto, Eduardo Faria Silva, Hermano Anjos Garcia, Francisco Carneiro
INTRODUCTION: Pancreatic cancer is the fourth major cause of cancer-related deaths. About 50% of the patients are diagnosed with advanced disease. Metastatic disease to the colon is a very rare entity with only 5 cases described in english literature. CASE PRESENTATION: Male, 60 years-old, presents to a surgical consult with the diagnosis of an adenocarcinoma of the sigmoid colon. The physical exam revealed a periumbilical nodule with suspicious features. The staging CT-scan showed a mass in the tail of the pancreas involving the spleen and left kidney, thickening of the sigmoid colon, multiple mesenteric masses and trabecular changes in the ischium, suggesting metastatic disease...
February 9, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29453972/artemin-regulates-cxcr4-expression-to-induce-migration-and-invasion-in-pancreatic-cancer-cells-through-activation-of-nf-%C3%AE%C2%BAb-signaling
#2
Juan Wang, Hui Wang, Jun Cai, Shaoxia Du, Beibei Xin, Wei Wei, Ti Zhang, Xiaohong Shen
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal human malignant tumor because of the early onset of local invasion and distant metastasis. Perineural invasion is a prominent characteristic of pancreatic adenocarcinoma, which is a multifactorial process that involves various signaling molecules from different signaling pathways. The glial cell line-derived neurotrophic factor family of ligands was reported to be involved in perineural invasion in pancreatic cancer. Artemin is one member of the glial cell line-derived neurotrophic factor family of ligands...
February 14, 2018: Experimental Cell Research
https://www.readbyqxmd.com/read/29442211/circulating-tumor-cells-predict-occult-metastatic-disease-and-prognosis-in-pancreatic-cancer
#3
Colin M Court, Jacob S Ankeny, Shonan Sho, Paul Winograd, Shuang Hou, Min Song, Zev A Wainberg, Mark D Girgis, Thomas G Graeber, Vatche G Agopian, Hsian-Rong Tseng, James S Tomlinson
BACKGROUND: Occult metastatic tumors, below imaging thresholds, are a limitation of staging systems that rely on cross-sectional imaging alone and are a cause of the routine understaging of pancreatic ductal adenocarcinomas (PDACs). We investigated circulating tumor cells (CTCs) as a preoperative predictor of occult metastatic disease and as a prognostic biomarker for PDAC patients. EXPERIMENTAL DESIGN: A total of 126 patients (100 with cancer, 26 with benign disease) were enrolled in our study and CTCs were identified and enumerated from 4 mL of venous blood using the microfluidic NanoVelcro assay...
February 13, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29440861/eyelashes-trichomegaly-an-unusual-side-effect-of-gefitinib-therapy
#4
Chaturbhuj R Agrawal, Pankaj Goyal, Dinesh Chandra Doval, Kumardeep Dutta, Kshitij Domadia, Silky Kothiwal
Evolution of targeted therapy has changed the spectrum of treatment in oncology since the past two decades as lots of newer agents are being added to the pharmacologic armamentarium of cancer therapy. Epidermal growth factor receptor inhibitors form one such advancing field with many newer agents being investigated and they are used in wide variety of malignancies such as head and neck cancer, lung cancer, and even gastrointestinal malignancies such as pancreatic cancer. Various troublesome side effects of these agents include diarrhea, severe fatigability, severe skin rashes, and deranged liver function tests which may require treatment interruption or dose reduction resulting in decreased response to treatment...
January 2018: International Journal of Trichology
https://www.readbyqxmd.com/read/29440233/comprehensive-characterisation-of-compartment-specific-long-non-coding-rnas-associated-with-pancreatic-ductal-adenocarcinoma
#5
Luis Arnes, Zhaoqi Liu, Jiguang Wang, Hans Carlo Maurer, Irina Sagalovskiy, Marta Sanchez-Martin, Nikhil Bommakanti, Diana C Garofalo, Dina A Balderes, Lori Sussel, Kenneth P Olive, Raul Rabadan
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is a highly metastatic disease with limited therapeutic options. Genome and transcriptome analyses have identified signalling pathways and cancer driver genes with implications in patient stratification and targeted therapy. However, these analyses were performed in bulk samples and focused on coding genes, which represent a small fraction of the genome. DESIGN: We developed a computational framework to reconstruct the non-coding transcriptome from cross-sectional RNA-Seq, integrating somatic copy number alterations (SCNA), common germline variants associated to PDA risk and clinical outcome...
February 10, 2018: Gut
https://www.readbyqxmd.com/read/29439298/a-rare-cause-of-pancreatic-head-mass-metastatic-prostate-cancer-a-case-report-and-review-of-literature
#6
Khalil Aloreidi, Robert T Lapp
Metastases to the pancreas account for less than 5 percent of all malignancies affecting the pancreas. The most common secondary malignancy of the pancreas is renal cell carcinoma. We report a patient presented with abdominal pain and weight loss. Computed tomography (CT) imaging showed pancreatic head mass. Biopsy from the mass showed prostate metastasis after 13 years from radical prostatectomy and Leuprolide therapy. This case demonstrates a rare location for prostate metastasis which was the pancreas. To our knowledge there are only six cases reported in literature...
January 2018: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/29436617/ripk4-pebp1-axis-promotes-pancreatic-cancer-cell-migration-and-invasion-by-activating-raf1-mek-erk-signaling
#7
Zi-Hao Qi, Hua-Xiang Xu, Shi-Rong Zhang, Jin-Zhi Xu, Shuo Li, He-Li Gao, Wei Jin, Wen-Quan Wang, Chun-Tao Wu, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
Pancreatic cancer is a lethal disease with a high metastatic potential. In our previous study, we identified a specific subgroup of patients with pancreatic cancer with a serum signature of carcinoembryonic antigen (CEA)+/cancer antigen (CA)125+/CA19-9 ≥1,000 U/ml. In this study, by using high-throughput screening analysis, we found that receptor-interacting protein kinases 4 (RIPK4) may be a key molecule involved in the high metastatic potential of this subgroup of patients with pancreatic cancer. A high RIPK4 expression predicted a poor prognosis and promoted pancreatic cancer cell migration and invasion via the RAF1/MEK/ERK pathway...
February 7, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29435042/investigation-into-metastatic-processes-and-the-therapeutic-effects-of-gemcitabine-on-human-pancreatic-cancer-using-an-orthotopic-suit-2-pancreatic-cancer-mouse-model
#8
Tamami Higuchi, Takehiko Yokobori, Tomoharu Naito, Chihaya Kakinuma, Shinji Hagiwara, Masahiko Nishiyama, Takayuki Asao
Prognosis of pancreatic cancer is poor, thus the development of novel therapeutic drugs is necessary. During preclinical studies, appropriate models are essential for evaluating drug efficacy. The present study sought to determine the ideal pancreatic cancer mouse model for reliable preclinical testing. Such a model could accurately reflect human pancreatic cancer phenotypes and predict future clinical trial results. Systemic pathology analysis was performed in an orthotopic transplantation model to prepare model mice for use in preclinical studies, mimicking the progress of human pancreatic cancer...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434873/mechanisms-by-which-cxcr4-cxcl12-cause-metastatic-behavior-in-pancreatic-cancer
#9
Jianbo Zhang, Chengxin Liu, Xinkai Mo, Huan Shi, Sheng Li
C-X-C motif chemokine receptor (CXCR) 4/CXCL12 is associated with tumor invasion and metastasis in pancreatic cancer. The present study aimed to investigate the possible mechanisms behind this process by studying the association between the expression of CXCR4 and numerous molecular markers. A total of 60 patients with pancreatic cancer who had been treated with radical surgery between July 2012 and February 2016 were included in the present study. The expression of CXCR4/CXCL12 in primary pancreatic cancer lesions, tissues adjacent to cancerous tissue, non-cancerous pancreatic tissues and in the surrounding lymph nodes was evaluated by immunohistochemistry...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29432846/nf-%C3%AE%C2%BAb-in-pancreatic-cancer-its-key-role-in-chemoresistance
#10
Quanxiao Li, Gang Yang, Mengyu Feng, Suli Zheng, Zhe Cao, Jiangdong Qiu, Lei You, Lianfang Zheng, Ya Hu, Taiping Zhang, Yupei Zhao
Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-κB) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance...
February 9, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29430219/disease-control-on-lanreotide-autogel%C3%A2-120-mg-in-a-patient-with-metastatic-gastrinoma-a-case-report
#11
Maridi Aerts, Hendrik Reynaert
Gastrinomas are functionally active pancreatic neuroendocrine tumors (NETs) secreting gastrin and are associated with local or regional metastases in 60% of the cases. Somatostatin analogs (SSAs) are currently recommended as a first-line treatment for the symptomatic treatment of NETs. Although antiproliferative activity of SSAs has been demonstrated in various cancer types in several in vivo and in vitro studies, clinical benefits with SSAs have been only achieved in a small proportion of patients. We report a disease control on a long-acting SSA lanreotide in a patient with metastatic gastrinoma...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29423221/a-phase-i-clinical-trial-of-dtcapfs-a-derivative-of-a-novel-human-hormone-peptide-for-the-treatment-of-advanced-metastatic-solid-tumors
#12
Salomon M Stemmer, Ofer Benjaminov, Michael H Silverman, Uziel Sandler, Ofer Purim, Naomi Sender, Chen Meir, Pnina Oren-Apoteker, Joel Ohana, Yoram Devary
The aim of the present phase I first-in-human study was to investigate the safety/efficacy of dTCApFs (a novel hormone peptide that enters cells through the T1/ST2 receptor), in advanced/metastatic solid tumors. The primary objective of this open-label dose-escalation study was to determine the safety profile of dTCApFs. The study enrolled patients (aged ≥18 years) with pathologically confirmed locally advanced/metastatic solid malignancies, who experienced treatment failure or were unable to tolerate previous standard therapy...
January 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29416754/targeted-deep-sequencing-of-circulating-tumor-dna-in-metastatic-pancreatic-cancer
#13
Andreas W Berger, Daniel Schwerdel, Thomas J Ettrich, Alexander Hann, Stefan A Schmidt, Alexander Kleger, Ralf Marienfeld, Thomas Seufferlein
Purpose: Precision medicine in pancreatic ductal adenocarcinoma (PDAC) could be substantially supported by tools that allow to establish and monitor the molecular setup of the tumor. In particular, noninvasive approaches are desirable, but not validated. Characterization of circulating tumor DNA (ctDNA) may help to achieve this goal. Experimental Design: Blood samples from patients with metastatic PDAC prior to and during palliative treatment were collected. ctDNA and corresponding tumor tissue were analyzed by targeted next generation sequencing and droplet digital PCR for the 7 most frequently mutated genes in PDAC (TP53, SMAD4, CDKN2A, KRAS, APC, ATM, and FBXW7)...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29398155/-interstitial-lung-disease-and-pancreatic-cancer-series-of-two-cases
#14
A Heraudeau, C Ricordel, A Sale, M Lederlin, M Kerjouan, B De Latour, F Llamas-Guttierez, B Desrues, S Jouneau
INTRODUCTION: Pancreatic cancer is often not diagnosed until at a metastatic stage at which point the prognosis is very poor. Pulmonary metastases are pleomorphic, often present at the time of diagnosis and can lead to the discovery of an asymptomatic primary disease. CASE REPORT: We describe two cases aged 60 and 74 years, where imaging identified what was thought to be an interstitial lung disease but which was actually metastasis from pancreatic cancer. In the first case, CT showed multiple excavated pulmonary nodules but the presentation with medullary compression led rapidly to pathological diagnosis on bone lesions...
February 1, 2018: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/29397891/modified-appleby-procedure-for-locally-advanced-pancreatic-cancer
#15
Shanley Deal, Derek Nathan, Flavio G Rocha
Locally advanced pancreas cancer (LAPC) involving the celiac axis is typically considered unresectable and carries a poor prognosis. We present a case of a patient with LAPC who underwent a modified Appleby procedure for tumor clearance following neoadjuvant therapy. Technical aspects include diagnostic laparoscopy to exclude occult metastatic disease followed by complete mobilization of the pancreas and spleen, preservation of the left gastric artery, and resection and reconstruction of the common hepatic artery...
January 10, 2018: American Journal of Surgery
https://www.readbyqxmd.com/read/29397631/development-of-epidermal-growth-factor-receptor-targeted-therapy-in-pancreatic-cancer
#16
Liu Qing, Wang Qing
The epidermal growth factor receptor (EGFR) family are a series of important cancer therapeutic targets involved in cancer biology. These genes play an important role in tumor biological characteristics including angiogenesis, cell survival, invasion and glucose metabolism. In recent years, progresses have been achieved upon the cellular and molecular biological characteristics of EGFR and its role in cancer development based on the study of tumor specimens and experimental animal model. EGFR(HER1/ErbB) is overexpressed in over sixty percent of triple-negative breast cancers and occurs in pancreatic, bladder, lung and head-and-neck cancers...
February 1, 2018: Minerva Chirurgica
https://www.readbyqxmd.com/read/29396858/recapitulating-the-clinical-scenario-of-brca-associated-pancreatic-cancer-in-pre-clinical-models
#17
Talia Golan, Chani Stossel, Dikla Atias, Ella Buzhor, Sharon Halperin, Keren Cohen, Maria Raitses-Gurevich, Yulia Glick, Stephen Raskin, Daniel Yehuda, Anna Feldman, Michael Schvimer, Eitan Friedman, Rotem Karni, Julie M Wilson, Robert E Denroche, Ilinca Lungu, John M S Bartlett, Faridah Mbabaali, Steven Gallinger, Raanan Berger
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. BRCA-associated PDAC comprises a clinically relevant subtype. A portion of these patients are highly susceptible to DNA damaging therapeutics, however, responses are heterogeneous and clinical resistance evolves. We have developed unique patient-derived xenograft (PDX) models from metastatic lesions of germline BRCA-mutated patients obtained at distinct time points; before treatment and at progression. Thus, closely mimicking clinical scenarios, to further investigate treatment naïve and resistant patients...
February 3, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29394808/-long-term-survival-after-multidisciplinary-treatment-for-resected-pancreatic-adenocarcinoma-with-recurrence-of-pulmonary-metastases-a-case-report
#18
Tadashi Tsukamoto, Makoto Takahama, Shintaro Kodai, Akishige Kanazawa, Takaaki Hori, Ryoji Kaizaki, Satoshi Takatsuka, Ryushi Komatsu
Recent studies indicated that isolated pulmonary metastases could define a favorable subgroup in metastatic pancreatic cancer. We report a case of isolated pulmonary metastases after curative resection of pancreas head cancer treated with chemotherapy and pulmonary metastasectomy survived for 79 months after recurrence. A 72-year-old male underwent pancreatoduodenectomy for pancreas head cancer. Adjuvant chemotherapy was done with gemcitabine hydrochloride (GEM)for 6 months and then S-1 for 2 months. Twenty-seven months after surgery, 2 small metastatic nodules in the left lung was detected...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394789/-a-case-of-gemcitabine-and-nab-paclitaxel-therapy-for-multiple-metastatic-pancreatic-cancer
#19
Yusuke Takashima, Jun Shibamoto, Yukino Kawamura, Maiko Nishida, Hidekazu Hiramoto, Fumiaki Ochi, Masahiro Tsujiura, Susumu Nakashima, Junshin Fujiyama, Mamoru Masuyama
Pancreatic cancer is one of the leading causes of cancer-related death in Japan. Nab-paclitaxel(nab-PTX)and gemcitabine( GEM)combination chemotherapysignificantlyimproved overall survival in a phase III trial(MPACT). This combination chemotherapyhas become one of the first-line treatments for patients with metastatic pancreatic cancer since December 2014. We report a case of a patient who underwent this chemotherapyfor recurrence of pancreatic head cancer. A 64-yearold man, who underwent curative resection of pancreatic cancer 2 years ago, relapsed with multiple lung metastases and a para-aortic nodal metastasis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394764/-the-treatment-outcomes-of-folfirinox-for-unresectable-and-recurrent-pancreatic-cancer
#20
Takuya Sakamoto, Yutaka Takeda, Yoshiaki Ohmura, Yoshiteru Katsura, Ryota Mori, Yohei Nose, Kenji Kawai, Kohei Murakami, Atsushi Naito, Junichi Inatome, Yoshinori Kagawa, Toru Masuzawa, Atsushi Takeno, Chiyomi Egawa, Kohei Murata
FOLFIRINOX is now considered to be a highly effective regimen for patients with metastatic pancreatic cancer. We administered FOLFIRINOX therapy in 18 patients between October 2014 and April 2017 as follows: 2-hour infusion of L-OHP at a dose of 85mg/m2, 2-hour infusion of LV at a dose of 200 mg/m2, infusion of CPT-11 for over 90 minutes at a dose of 150 mg/m2, followed by continuous infusion of 5-FU over 46 hours at a dose of 2,400mg/m2. The median age of the patients was 66.5 years. There were 15 patients with performance status(PS)0, and 3 with PS 1...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
31154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"